Chemically treated plasma A? is a potential blood-based biomarker for screening cerebral amyloid deposition.

ABSTRACT:

Background

Plasma ?-amyloid (A?) is a potential candidate for an Alzheimer's disease (AD) biomarker because blood is an easily accessible bio-fluid, which can be collected routinely, and A? is one of the major hallmarks of AD pathogenesis in the brain. However, the association between plasma A? levels and AD diagnosis is still unclear due to the instability and inaccurate measurements of plasma A? levels in the blood of patients with AD. If a consistent value of plasma A? from the blood can be obtained, this might help determine whether plasma A? is a potential biomarker for AD diagnosis.

Methods

We predicted the brain amyloid deposit by measuring the plasma A? levels. This cross-sectional study included 353 participants (215 cognitively normal, 79 with mild cognitive impairment, and 59 with AD dementia) who underwent Pittsburgh-compound B positron emission tomography (PiB-PET) scans. We treated a mixture of protease inhibitors and phosphatase inhibitors (MPP) and detected plasma A?42 and A?40 (MPP-A?42 and MPP-A?40) in a stable manner using xMAP technology.

Results

MPP-A?40 and MPP-A?42/40 (MPP-A?s) were significantly different between subjects with positive amyloid deposition (PiB+) and those with negative amyloid deposition (PiB-) (P?ConclusionsMPP-A? might be one of the potential blood biomarkers for the prediction of PiB-PET positivity in the brain.

SUBMITTER: Park JC 

PROVIDER: S-EPMC5361707 | biostudies-literature | 2017 Mar

REPOSITORIES: biostudies-literature